JP2009528991A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009528991A5 JP2009528991A5 JP2008555308A JP2008555308A JP2009528991A5 JP 2009528991 A5 JP2009528991 A5 JP 2009528991A5 JP 2008555308 A JP2008555308 A JP 2008555308A JP 2008555308 A JP2008555308 A JP 2008555308A JP 2009528991 A5 JP2009528991 A5 JP 2009528991A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- disease
- compound according
- halo
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001931 aliphatic group Chemical group 0.000 claims 46
- 150000001875 compounds Chemical class 0.000 claims 29
- 239000003814 drug Substances 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 22
- 125000005843 halogen group Chemical group 0.000 claims 19
- 229920006395 saturated elastomer Polymers 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000020084 Bone disease Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 206010039083 rhinitis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- -1 C 3-8 cycloaliphatic Chemical group 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000003900 neurotrophic factor Substances 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000035939 Alveolitis allergic Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000027445 Farmer Lung Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039088 Rhinitis atrophic Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 201000009151 chronic rhinitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 208000022195 farmer lung disease Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77314306P | 2006-02-14 | 2006-02-14 | |
| PCT/US2007/003767 WO2007095223A2 (en) | 2006-02-14 | 2007-02-12 | Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009528991A JP2009528991A (ja) | 2009-08-13 |
| JP2009528991A5 true JP2009528991A5 (https=) | 2010-03-11 |
Family
ID=38180574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008555308A Pending JP2009528991A (ja) | 2006-02-14 | 2007-02-12 | プロテインキナーゼの阻害剤として有用なピロロ（３，２−ｃ）ピリジン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7659283B2 (https=) |
| EP (1) | EP2004645A2 (https=) |
| JP (1) | JP2009528991A (https=) |
| CN (1) | CN101848909A (https=) |
| AU (1) | AU2007215161A1 (https=) |
| CA (1) | CA2641254A1 (https=) |
| WO (1) | WO2007095223A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1831225A2 (en) | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
| UA95940C2 (uk) | 2006-01-17 | 2011-09-26 | Вертекс Фармасьютикалс Інкорпорейтед | Азаіндоли як інгібітори кіназ януса |
| WO2007114926A2 (en) | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Kinase antagonists |
| CN101678022A (zh) | 2006-12-21 | 2010-03-24 | 弗特克斯药品有限公司 | 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物 |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| JP2011513483A (ja) * | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| EP2252293B1 (en) | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
| BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| LT3141252T (lt) | 2009-06-17 | 2018-11-12 | Vertex Pharmaceuticals Inc. | Gripo virusų replikacijos inhibitoriai |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| KR101173678B1 (ko) | 2010-10-20 | 2012-08-13 | 한국과학기술연구원 | 피롤로[3,2-ｃ]피리딘 유도체 및 그의 제조 방법 |
| RU2013132681A (ru) | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| JP2015532287A (ja) | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｉｒｅ１の調節 |
| AU2014291161B2 (en) | 2013-07-18 | 2018-04-26 | Taiho Pharmaceutical Co., Ltd. | Antitumor drug for intermittent administration of FGFR inhibitor |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| LT3068776T (lt) | 2013-11-13 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Gripo virusų replikacijos inhibitoriai |
| JP6618901B2 (ja) | 2013-11-13 | 2019-12-11 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| MX2017001103A (es) * | 2014-07-31 | 2017-04-27 | Merck Patent Gmbh | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. |
| EP3294735B8 (en) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| CN109071455B (zh) | 2016-03-11 | 2022-08-02 | 嘉兴和剂药业有限公司 | 用于调节布鲁顿酪氨酸激酶的化合物及方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997034895A1 (de) * | 1996-03-15 | 1997-09-25 | Novartis Ag | NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
| BR9812944A (pt) | 1997-10-20 | 2000-08-08 | Hoffmann La Roche | Inibidores bicìclicos da cinase |
| ID29028A (id) * | 1998-09-18 | 2001-07-26 | Basf Ag | Pirolopirimidina sebagai penghambat protein kinase |
| ES2253930T3 (es) * | 1998-09-18 | 2006-06-01 | ABBOTT GMBH & CO. KG | 4-aminopirrolopirimidinas como inhibidores de quinasa. |
| CA2348740A1 (en) * | 1998-12-23 | 2000-07-06 | Ruth R. Wexler | Thrombin or factor xa inhibitors |
| US20040235867A1 (en) * | 2001-07-24 | 2004-11-25 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| US20050026944A1 (en) * | 2003-07-24 | 2005-02-03 | Patrick Betschmann | Thienopyridine and furopyridine kinase inhibitors |
| TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| CA2572058A1 (en) * | 2004-06-30 | 2006-01-12 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
| WO2006114180A1 (de) | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
-
2007
- 2007-02-12 WO PCT/US2007/003767 patent/WO2007095223A2/en not_active Ceased
- 2007-02-12 US US11/705,556 patent/US7659283B2/en not_active Expired - Fee Related
- 2007-02-12 EP EP07750595A patent/EP2004645A2/en not_active Withdrawn
- 2007-02-12 JP JP2008555308A patent/JP2009528991A/ja active Pending
- 2007-02-12 AU AU2007215161A patent/AU2007215161A1/en not_active Abandoned
- 2007-02-12 CA CA002641254A patent/CA2641254A1/en not_active Abandoned
- 2007-02-12 CN CN200780012623A patent/CN101848909A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009528991A5 (https=) | ||
| JP2009506123A5 (https=) | ||
| JP2009526849A5 (https=) | ||
| JP2003507456A5 (https=) | ||
| JP2015528447A5 (https=) | ||
| JP2021176902A (ja) | ピロロ［１，２−ｂ］ピリダジン誘導体 | |
| JP2021504443A (ja) | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 | |
| JP2007519742A5 (https=) | ||
| JP2009507792A5 (https=) | ||
| JP2005528443A5 (https=) | ||
| JP2009532475A5 (https=) | ||
| RU2012142550A (ru) | Производные пирролопиразина и их применение в качестве ингибиторов jak и syk | |
| JP2017531002A5 (https=) | ||
| JP2022505525A5 (https=) | ||
| JP2020503010A5 (https=) | ||
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| EP3269711B1 (en) | Stable apremilast crystal form ii free of solvates, and preparation method therefor | |
| HRP20161010T1 (hr) | C5ar antagonisti | |
| JP2018536705A5 (https=) | ||
| RU2006109108A (ru) | Соединения, обладающие активностью антагонистов crth2 рецепторов | |
| JP2011520896A5 (https=) | ||
| JP2007513072A5 (https=) | ||
| CA2936551A1 (en) | Substituted pyrrolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases | |
| CA2491895A1 (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
| JP2010509342A5 (https=) |